Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more
Xenon Pharmaceuticals Inc (XENE) - Net Assets
Latest net assets as of December 2025: $581.76 Million USD
Based on the latest financial reports, Xenon Pharmaceuticals Inc (XENE) has net assets worth $581.76 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($981.67 Million) and total liabilities ($399.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $581.76 Million |
| % of Total Assets | 59.26% |
| Annual Growth Rate | 34.27% |
| 5-Year Change | 5.77% |
| 10-Year Change | 810.41% |
| Growth Volatility | 89.16 |
Xenon Pharmaceuticals Inc - Net Assets Trend (2012–2025)
This chart illustrates how Xenon Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xenon Pharmaceuticals Inc (2012–2025)
The table below shows the annual net assets of Xenon Pharmaceuticals Inc from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $581.76 Million | -22.94% |
| 2024-12-31 | $754.90 Million | -18.65% |
| 2023-12-31 | $927.92 Million | +28.61% |
| 2022-12-31 | $721.50 Million | +31.17% |
| 2021-12-31 | $550.03 Million | +220.99% |
| 2020-12-31 | $171.35 Million | +86.30% |
| 2019-12-31 | $91.98 Million | -10.96% |
| 2018-12-31 | $103.30 Million | +187.46% |
| 2017-12-31 | $35.93 Million | -43.77% |
| 2016-12-31 | $63.90 Million | +4.70% |
| 2015-12-31 | $61.03 Million | -16.14% |
| 2014-12-31 | $72.78 Million | +201.79% |
| 2013-12-31 | $24.12 Million | +91.05% |
| 2012-12-31 | $12.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xenon Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 111659600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.60 Billion | 274.78% |
| Other Comprehensive Income | $335.00K | 0.06% |
| Other Components | $228.23 Million | 39.23% |
| Total Equity | $581.76 Million | 100.00% |
Xenon Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Xenon Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Enagás S.A
PINK:ENGGF
|
$3.24 Billion |
|
Avic Aviation High Technology Co Ltd
SHG:600862
|
$3.24 Billion |
|
Henan Zhongfu Industrial Co Ltd
SHG:600595
|
$3.24 Billion |
|
Legend Biotech Corp
NASDAQ:LEGN
|
$3.25 Billion |
|
La Francaise Des Jeux Sa
PA:FDJ
|
$3.24 Billion |
|
Sichuan Huafeng Technology Co. Ltd. A
SHG:688629
|
$3.23 Billion |
|
Avista Corporation
NYSE:AVA
|
$3.23 Billion |
|
Zheshang Securities Co Ltd
SHG:601878
|
$3.23 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xenon Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 754,903,000 to 581,760,000, a change of -173,143,000 (-22.9%).
- Net loss of 345,910,000 reduced equity.
- Other comprehensive income increased equity by 1,947,000.
- Other factors increased equity by 170,820,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-345.91 Million | -59.46% |
| Other Comprehensive Income | $1.95 Million | +0.33% |
| Other Changes | $170.82 Million | +29.36% |
| Total Change | $- | -22.94% |
Book Value vs Market Value Analysis
This analysis compares Xenon Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.52x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 5.82x to 7.52x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $9.48 | $55.20 | x |
| 2013-12-31 | $2.45 | $55.20 | x |
| 2014-12-31 | $5.24 | $55.20 | x |
| 2015-12-31 | $4.27 | $55.20 | x |
| 2016-12-31 | $4.12 | $55.20 | x |
| 2017-12-31 | $2.00 | $55.20 | x |
| 2018-12-31 | $5.32 | $55.20 | x |
| 2019-12-31 | $3.55 | $55.20 | x |
| 2020-12-31 | $4.96 | $55.20 | x |
| 2021-12-31 | $12.61 | $55.20 | x |
| 2022-12-31 | $11.92 | $55.20 | x |
| 2023-12-31 | $13.87 | $55.20 | x |
| 2024-12-31 | $9.69 | $55.20 | x |
| 2025-12-31 | $7.34 | $55.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xenon Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4612.13%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.69x
- Recent ROE (-59.46%) is below the historical average (-25.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -34.07% | -30.06% | 0.23x | 5.02x | $-5.56 Million |
| 2013 | 49.89% | 43.98% | 0.50x | 2.26x | $9.62 Million |
| 2014 | 17.89% | 45.89% | 0.32x | 1.20x | $5.74 Million |
| 2015 | -25.81% | -101.12% | 0.24x | 1.05x | $-21.86 Million |
| 2016 | -35.99% | -1275.49% | 0.03x | 1.06x | $-29.39 Million |
| 2017 | -85.45% | -9872.67% | 0.01x | 1.28x | $-34.30 Million |
| 2018 | -33.40% | 0.00% | 0.00x | 1.19x | $-44.83 Million |
| 2019 | -45.22% | -609.09% | 0.05x | 1.61x | $-50.79 Million |
| 2020 | -16.83% | -89.65% | 0.17x | 1.10x | $-45.97 Million |
| 2021 | -14.34% | -427.85% | 0.03x | 1.04x | $-133.89 Million |
| 2022 | -17.38% | -1328.95% | 0.01x | 1.05x | $-197.52 Million |
| 2023 | -19.66% | 0.00% | 0.00x | 1.04x | $-275.19 Million |
| 2024 | -31.04% | 0.00% | 0.00x | 1.06x | $-309.82 Million |
| 2025 | -59.46% | -4612.13% | 0.01x | 1.69x | $-404.09 Million |
Industry Comparison
This section compares Xenon Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xenon Pharmaceuticals Inc (XENE) | $581.76 Million | -34.07% | 0.69x | $3.24 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |